Rankings
▼
Calendar
KNSA Q4 2021 Earnings — Kiniksa Pharmaceuticals, Ltd. Revenue & Financial Results | Market Cap Arena
KNSA
Kiniksa Pharmaceuticals, Ltd.
$3B
Q4 2021 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$19M
Gross Profit
$15M
79.4% margin
Operating Income
-$36M
-192.8% margin
Net Income
-$36M
-193.8% margin
EPS (Diluted)
$-0.53
QoQ Revenue Growth
+55.0%
Cash Flow
Operating Cash Flow
-$19M
Free Cash Flow
-$19M
Stock-Based Comp.
$6M
Balance Sheet
Total Assets
$233M
Total Liabilities
$48M
Stockholders' Equity
$185M
Cash & Equivalents
$122M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$19M
$0
—
Gross Profit
$15M
$0
—
Operating Income
-$36M
-$53M
+31.7%
Net Income
-$36M
-$54M
+32.3%
← FY 2021
All Quarters
Q1 2022 →